I. UNDERWITER LIST

II. FIRM ANALYSTS

I. UNDERWITER LIST

Allen & Company LLC.
Ameritrade, Inc.
Banc of America Securities
Blackstone Group
Barclays Bank PLC
Bear, Stearns & Co. Inc.
BNP Paribas Peregrine Capital Limited.
Canadian Imperial Bank of Commerce.
Cazenove Asia Limited.
Cazenove Inc.
Charles Stanley Securities (UK)
China Everbright Capital Limited. (CHINA)
China International Capital Corporation Limited. (CHINA)
CIBC World Markets Corp.
Citigroup Global Markets Inc.
Co-Manager(s) Advest, Inc.
Credit Suisse First Boston LLC.
Daiwa Securities SMBC Hong Kong Limited.
Deutsche Bank Securities Inc.
E*TRADE Securities LLC.
Evercore Partners
Oppenheimer & Co. Inc.
Ferris, Baker Watts Inc.
Fidelity Capital Markets, a division of National Financial Services, LLC.
Fixed Income Securities LLC
Fox-Pitt, Kelton Inc.
Greenhill & Co
Huntleigh Securities Corporation
Harris Nesbitt Corp.
HARRISdirect, LLC
ICEA Capital Limited.
ING Bank N.V.
Janney Montgomery Scott LLC
Jefferies & Company, Inc.
J.P. Morgan Securities Inc.
Keefe Bruyette & Woods Inc
Lazard Freres & Co. LLC.
Lehman Brothers Holdings Inc. (LEH)
M.R. Beal & Company.
Merrill Lynch & Co., Inc. (MER)
Morgan Stanley & Co. Incorporated (MS)
Muriel Siebert & Co. Inc.
Needham & Company, Inc.
Nomura Securities
Pacific Growth Equities, LLC.
RBC Financial Group
Piper Jaffray & Co.
Rothschild
Samuel A. Ramirez & Co., Inc.
Sanders Morris Harris
Sands Brothers & Co., Ltd.
Stifel, Nicolaus & Company
Sullivan & Cromwell LLP
SunTrust Robinson Humphrey
The Goldman Sachs Group, Inc. (GS)
Thomas Weisel Partners LLC.
UBS Securities LLC.
Utendahl Capital Group, L.L.C.
Wachovia Capital Markets, LLC.
Wedbush Morgan Securities
Wells Fargo Securities, LLC.
William Blair & Company L.L.C.
WR Hambrecht + Co., LLC.

II. FIRM ANALYSTS

A.G. Edwards & Sons, Inc. Alex Hittle 314.955.5177
American Technology Research Manoj Garg
Banc of America Securities: David Witzke 212.847.6023
BANC OF AMERICA SECURITIES: Frank Pinkerton +212 583 8043
BEAR STEARNS: Steve Unger +212 272 5173
Black Diamond Research Antony Pfaffle 212.994.3773
Buckingham Research Group: David G. Buck
CIBC World Markets: Bret Holley, Ph.D. 212.667.7289
CIBC World Markets: Elliot Wilbur, CFA
CIBC WORLD MARKETS: Mara Goldstein +212 667 8112
Credit Suisse First Boston, Inc.: Mark E. Augustine 212.325.3487
First Albany Capital: Adam Greene
First Analysis Securities: Tracy Marshbanks
Friedman Billings Ramsey: Jim Reddoch 703.312.9762
Friedman Billings Ramsey: Robert H. Uhl
FRIEDMAN, BILLINGS, RAMSEY GROUP, INC.: James Kumple +703 312 1721
GARP RESEARCH: Brett Carson +410 825 6600
GOLDMAN SACHS: Chris McFadden +212 357-0136
Goldman Sachs: May-Kin Ho, Ph.D. 212.902.6723
J. P. Morgan: Jeff Zekauskas
JEFFERIES & CO: David Windley +615 963 8313
JMP Securities: Charles Duncan 415.835.8991
JPMorgan: Geoffrey Meacham 212.622.6531
KeyBanc: Mike Sison
Leerink Swann: Howard Liang 617.918.4857
Lehman Brothers: Craig Parker 415.263.4479
LEHMAN BROTHERS: Larry Marsh +212 526 5315
Lehman Brothers: Lei Huang / Rich Silver
Longbow Research: Dmitry Silversteyn
Merrill Lynch & Co.: Gregory B. Gilbert
Merrill Lynch Thomas: McGahren 212.229.3462
MERRIMAN CURHAN FORD & COMPANY: Raj Sharma +415 248 5631
Morgan Stanley: Sapna Srivastava 212.761.4097
Natexis Bleichroeder Timothy Chiang
Piper Jaffray Deb Knobelman
Robert W. Baird & Co., Inc. Christopher J. Raymond 312.609.5437
ROBERT W. BAIRD & CO., INC.: Eric W. Coldwell +312 609 5467
S G Cowen & Co. Ken Cacciatore
SG Cowen Securities, Inc. Phil Nadeau 212.278.4513
Smith Barney Citigroup: Yaron Werber 212.816.8836
SunTrust Robinson Humphrey: Han Li, Ph.D. 212.391.3808
Thomas Weisel Partners: Maneesh Jain 212.271.3620
THOMAS WEISEL: Steve Halper +212 271 3807
UBS： David Molowa 212.713.2105
US Bancorp Piper Jaffray: Thomas Wei 212.284.9305
WILLIAM BLAIR & CO.: John Kreger +312 364 8597

Note: This list may not be complete and is subject to change. YalePharma is providing this listing solely as a service to its shareholders and the investing public. By doing so, the Company does not imply its endorsement of or agreement with any information, opinions, recommendations or projections made by these analysts with respect to YalePharma and hereby disclaims any responsibility or liability arising from any reliance on this information.